Outcomes for R-CHOP Worse in Morning for Female Patients With Lymphoma

MONDAY, Feb. 6, 2023 -- Female patients with diffuse large B-cell lymphoma (DLBCL) have worse outcomes when receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the morning, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news